Navigation Links
MacroGenics' Board of Directors Elects Paulo F. Costa as Chairman
Date:9/19/2013

ROCKVILLE, Md., Sept. 19, 2013 /PRNewswire/ -- MacroGenics, Inc. today announced its Board of Directors has elected Paulo F. Costa as its new Chairman. The company also announced that Dr. David C. Stump is joining its Board of Directors, both effective September 18, 2013.

Paulo Costa has served on MacroGenics' Board as a Director since 2009.  Mr. Costa was the former Chairman of the Board of Amylin Pharmaceuticals, Inc. and is the former President and Chief Executive Officer of Novartis U.S. Corporation. While at Novartis, he held a number of other roles including Head of the Americas, and President and Chief Executive Officer of Novartis Pharmaceuticals Corporation, Novartis' largest pharmaceutical business. He was responsible for the entire General Medicine business in North and Latin America. Prior to joining Novartis, Mr. Costa worked at Johnson & Johnson for 30 years, where he served as President of Janssen Pharmaceutica, Executive Vice President, Global Franchise Development, and was a member of Johnson & Johnson's Pharmaceutical Group Operating Committee. He has more than 25 years of general management experience, having launched over 10 pharmaceutical products in various therapeutic areas in the U.S. market. Mr. Costa earned his M.B.A. from Harvard Business School and is a graduate of the Sao Paulo School of Business Administration, in Brazil.  He is currently a member of the Board of Directors of Purdue Pharma Inc., Helsinn Therapeutics Inc. and Oncology Trials Insights.

"Over the past several years, I have had the great opportunity to work closely with Paulo and have been impressed with his leadership and the depth and breadth of his industry knowledge," said Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics. "We are very pleased to welcome Paulo as the new Chair of our Board of Directors.  His proven skills in operations and commercialization are vital assets to MacroGenics."

Dr. David Stump was most recently Executive Vice President, Research and Development at Human Genome Sciences, Inc., (HGS) and joined the company in 1999. Prior to joining HGS, he held roles of increasing responsibility at Genentech, Inc., from 1989 to 1999, most recently as Vice President, Clinical Research and Genentech Fellow. Prior to joining Genentech, Dr. Stump was an Associate Professor of Medicine and Biochemistry at the University of Vermont. He earned an A.B. from Earlham College and an M.D. at Indiana University, followed by residency and fellowship training in internal medicine, hematology, oncology and biochemistry at the University of Iowa. He is currently a member of the Board of Directors of Sunesis Pharmaceuticals, Inc. and Dendreon Corp. as well as of the Board of Trustees of Earlham College.

"We welcome David to the Board of Directors of MacroGenics. His extensive leadership experience in clinical research and R&D and strong track record in the healthcare industry, make him an essential addition to the Board," said Scott Koenig.

Dr. Stump is replacing Board member Michael Steinmetz, Ph.D., Managing Director of Clarus Ventures, LLC.

"We want to thank Michael for his dedicated service and his contributions to MacroGenics' Board of Directors," added Scott Koenig. "It has been a real pleasure working with Michael over the last 13 years."

About MacroGenics, Inc.

MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. The company generates its pipeline of product candidates from its proprietary suite of next-generation antibody technology platforms, which it believes improve the performance of monoclonal antibodies and antibody-derived molecules. The company creates both differentiated molecules that are directed to novel cancer targets, as well as "bio-betters," which are drugs designed to improve upon marketed medicines. The combination of MacroGenics' technology platforms and antibody engineering expertise has allowed the company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies.   www.macrogenics.com

Statements made in this press release that are not historical facts are forward-looking statements. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company's ability to raise additional capital, and risks related to the Company's ability to initiate, and enroll patients in, planned clinical trials. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements


'/>"/>
SOURCE MacroGenics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. ImaginAb and MacroGenics Collaborate to Develop In Vivo Imaging Agents for Autoimmune Diseases, Cancer
2. MacroGenics Appoints Jon Wigginton, M.D., as Senior Vice President, Clinical Development
3. MacroGenics to Receive $10 Million Milestone Payment from Servier for Dosing the First Patient in a Phase 1 Dose Expansion Trial of MGA271
4. Academy of Managed Care Pharmacy (AMCP) Installs 2012-2013 Board of Directors
5. Angeion Selects Hendrik Struik for Board of Directors
6. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
7. The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Gen-Probe Incorporated in Connection with the Sale of the Company to Hologic, Inc.
8. Novogen Board Approves US$4 Million Investment In Marshall Edwards Rights Offering
9. Young Innovations, Inc. Board Of Directors Declares Quarterly Dividend
10. Allscripts Adds Two Independent Directors to Board
11. Generex Announces New Members of Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... 2017 Summary ... as a Key Component of Multichannel Marketing" provides ... landscape in the digital age. While the ... medical advancements, it has been much slower to ... on traditional channels and methods. However, the decreasing ...
(Date:3/28/2017)... , March 29, 2017 Center ... Siteless CRO platform, announced today study results presented ... Care Pharmacy, #AMCP2017, Managed Care and Specialty Pharmacy ... . Data in both posters demonstrated that pharmacist-led patient ... protocol adherence. These factors are crucial to generating the ...
(Date:3/28/2017)... CAMBRIDGE , United Kingdom and  BOSTON ... text analytics provider Linguamatics today announced ... Dow Jones . The agreement allows pharmaceutical companies ... utilizing Linguamatics I2E text mining technology. ... used by 18 of the top 20 global ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 28, 2017 , ... Z-Medica, LLC, a leading developer ... Center (UPMC) will acquire QuikClot® Bleeding Control Kits® (BCK) to equip up to ... with efforts by the American College of Surgeons, U.S. Department of Defense, Department ...
(Date:3/28/2017)... ... 28, 2017 , ... Award-winning medical group Allied Anesthesia today ... board chair for Orange County health care system CalOptima Friday. CalOptima announced its ... chair Mark Refowitz’s term, which runs through June 30 of this year, until ...
(Date:3/28/2017)... Appleton, WI (PRWEB) , ... March 28, 2017 ... ... how self-funded health plans work, the Self-Funding Success website has recently developed and ... about Self-Funded Health Plans ” was created based on common inquiries the site’s ...
(Date:3/28/2017)... , ... March 28, 2017 , ... ... of SkyLex Advanced Surgical, Inc. is thrilled to offer the recently FDA-approved Obalon ... and this procedure adds to SkyLex Advanced Surgical’s already comprehensive list of ...
(Date:3/28/2017)... ... ... Oily skin is a common and unwelcomed occurrence in people of all ages, genders and ... to the discussion of dealing with excess skin oil. “Oily skin is a challenge to ... can help remove the oily shine while keeping the skin fresh and clean,” says Dr. ...
Breaking Medicine News(10 mins):